DV Biomed CoROCO:6539 -0.24%68 EV-to-FCF is 42.79 as of Jul. 05, 2026, which is 59% above its 10-year median of 26.94. GuruFocus rates ROCO:6539 with a GF Score™ of 68/100 and a GF Value™ of NT$70.47 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 562 Drug Manufacturers companies, DV Biomed Co ranks worse than 69.57% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, DV Biomed Co's Enterprise Value is NT$731.9 Mil.
DV Biomed Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$17.1 Mil. Therefore, DV Biomed Co's EV-to-FCF for today is 42.79.
The historical rank and industry rank for DV Biomed Co's EV-to-FCF or its related term are showing as below:
ROCO:6539'
s EV-to-FCF Range Over the Past 10 Years
Min: 5.79 Med: 26.94 Max: 599.05
Current: 42.79
During the past 13 years, the highest EV-to-FCF of DV Biomed Co was 599.05. The lowest was 5.79. And the median was 26.94.
ROCO:6539's EV-to-FCF is ranked worse than 69.57% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.525
vs ROCO:6539: 42.79
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
DV Biomed Co's PE Ratio (TTM) for today is calculated as:
DV Biomed Co's share price for today is NT$41.65.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. DV Biomed Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.320.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
DV Biomed Co EV-to-FCF Related Terms
DV Biomed Co EV-to-FCF Historical Data
* Premium members only.
The historical data trend for DV Biomed Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DV Biomed Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DV Biomed Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DV Biomed Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where DV Biomed Co's EV-to-FCF falls into.
DV Biomed Co's current Enterprise Value is NT$731.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. DV Biomed Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$17.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DV Biomed Co (ROCO:6539) has a EV-to-FCF of 42.79 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on DV Biomed Co and its competitors. This is 59% above median its historical median of 26.94. Over the past decade, DV Biomed Co's EV-to-FCF has ranged from 5.79 to 599.05. According to the industry distribution chart, DV Biomed Co ranks #391 out of 562 companies in the Drug Manufacturers industry, placing it in the top 69.6%.
Is DV Biomed Co's EV-to-FCF too high?
DV Biomed Co's current EV-to-FCF of 42.79 is 59% above median its 10-year median of 26.94. Over the past 10 years, this metric has ranged from a low of 5.79 to a high of 599.05. The Drug Manufacturers industry median EV-to-FCF is 20.53. DV Biomed Co's value of 42.79 is 108.5% above this industry median. Based on the distribution chart, DV Biomed Co ranks #391 out of 562 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, DV Biomed Co has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does DV Biomed Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, DV Biomed Co ranks #391 out of 562 companies for EV-to-FCF. This places DV Biomed Co in the lower half of its industry. The industry median EV-to-FCF is 20.53. DV Biomed Co's value of 42.79 is 108.5% above this benchmark. Historically, DV Biomed Co's own EV-to-FCF has ranged from 5.79 to 599.05 over the past decade. While the company's 10-year median is 26.94 vs. the industry median of 20.53, DV Biomed Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.53, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DV Biomed Co's current EV-to-FCF of 42.79 is 108.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on DV Biomed Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DV Biomed Co's current EV-to-FCF is 42.79, which is 59% above median its own 10-year median of 26.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DV Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, DV Biomed Co (ROCO:6539) is currently considered Possible Value Trap. The stock's GF Value™ is NT$70.47, compared to a current price of NT$41.65 — trading 40.9% below its estimated fair value. The current EV-to-FCF is 42.79, which is 59% above median its 10-year median of 26.94 and 108.5% above the Drug Manufacturers industry median of 20.53. DV Biomed Co's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For DV Biomed Co (ROCO:6539), the current EV-to-FCF is 42.79 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DV Biomed Co (ROCO:6539) Overvalued in 2026?
Based on GuruFocus' analysis, DV Biomed Co stock appears to be undervalued.
The current stock price of NT$41.65 is trading 40.9% below its estimated GF Value™ of NT$70.47.
GuruFocus considers DV Biomed Co to be Possible Value Trap.
Key valuation signals for ROCO:6539:
EV-to-FCF: 42.79 (59% above median its 10-year median of 26.94)
GF Value™: NT$70.47 vs. price of NT$41.65 (40.9% below fair value)
Industry Position: 108.5% above the Drug Manufacturers median (#391 of 562)
No single metric tells the full story. See the ROCO:6539 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DV Biomed Co Ltd provides medical supplies, skincare, and healthcare products. Its products include Perfectin and L'AMOUR Isis. The company also provides medical materials and needles (medicine), and healthcare products.
68GF Score
Get the complete analysis for ROCO:6539
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6539 has been successfully added to your 
